Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors

Eric M. Thompson, Daniel J. Guillaume, Edit Dósa, Xin Li, Kellie Nazemi, Seymur Gahramanov, Bronwyn Hamilton, Edward Neuwelt

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Ferumoxytol, an iron nanoparticle used as an intravascular contrast agent for perfusion magnetic resonance imaging (MRI), has never been explored in the pediatric population. The purpose of this prospective study is to characterize the vascular and permeability properties of pediatric brain tumors using two contrast agents during a single imaging session: ferumoxytol for dynamic susceptibility weighted contrast (DSC) MRI and gadoteridol for dynamic contrast-enhanced (DCE) MRI. In a single imaging session, patients received intravenous ferumoxytol for DSC MRI followed by gadoteridol for DCE MRI. Relative cerebral blood volume (rCBV), relative cerebral blood flow (rCBF), transfer coefficient (Ktrans), and extravascular extracellular space volume fraction (ve) of the brain lesions were calculated. Patients underwent serial imaging sessions over the course of 2 years. Of the 7 patients enrolled thus far, none has experienced an adverse event. Two patients with medulloblastoma were enrolled preoperatively. In the first, rCBVmax, rCBF, Ktrans max, and ve max values were 3.74, 3.12, 0.47 min -1, and 0.08, respectively, while in the second patient, rCBVmax, rCBF, Ktrans max, and ve max values were 4.72, 3.47, 0.60 min-1, and 0.05, respectively. Four patients were enrolled after new gadolinium enhancement was noted in the tumor resection cavity. In 80 % of these lesions, rCBV was

Original languageEnglish (US)
Pages (from-to)105-114
Number of pages10
JournalJournal of Neuro-Oncology
Volume109
Issue number1
DOIs
StatePublished - Aug 2012

Fingerprint

Magnetic Resonance Angiography
Brain Neoplasms
Cerebrovascular Circulation
Ferrosoferric Oxide
Pediatrics
Magnetic Resonance Imaging
Contrast Media
Medulloblastoma
Gadolinium
Extracellular Space
Capillary Permeability
Nanoparticles
Iron
Prospective Studies
Brain
Population
Neoplasms

Keywords

  • Brain tumor
  • DCE MRI
  • DSC MRI
  • Ferumoxytol
  • Pediatric

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. / Thompson, Eric M.; Guillaume, Daniel J.; Dósa, Edit; Li, Xin; Nazemi, Kellie; Gahramanov, Seymur; Hamilton, Bronwyn; Neuwelt, Edward.

In: Journal of Neuro-Oncology, Vol. 109, No. 1, 08.2012, p. 105-114.

Research output: Contribution to journalArticle

@article{24c010fb13eb4135b0d79eeed5c72200,
title = "Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors",
abstract = "Ferumoxytol, an iron nanoparticle used as an intravascular contrast agent for perfusion magnetic resonance imaging (MRI), has never been explored in the pediatric population. The purpose of this prospective study is to characterize the vascular and permeability properties of pediatric brain tumors using two contrast agents during a single imaging session: ferumoxytol for dynamic susceptibility weighted contrast (DSC) MRI and gadoteridol for dynamic contrast-enhanced (DCE) MRI. In a single imaging session, patients received intravenous ferumoxytol for DSC MRI followed by gadoteridol for DCE MRI. Relative cerebral blood volume (rCBV), relative cerebral blood flow (rCBF), transfer coefficient (Ktrans), and extravascular extracellular space volume fraction (ve) of the brain lesions were calculated. Patients underwent serial imaging sessions over the course of 2 years. Of the 7 patients enrolled thus far, none has experienced an adverse event. Two patients with medulloblastoma were enrolled preoperatively. In the first, rCBVmax, rCBF, Ktrans max, and ve max values were 3.74, 3.12, 0.47 min -1, and 0.08, respectively, while in the second patient, rCBVmax, rCBF, Ktrans max, and ve max values were 4.72, 3.47, 0.60 min-1, and 0.05, respectively. Four patients were enrolled after new gadolinium enhancement was noted in the tumor resection cavity. In 80 {\%} of these lesions, rCBV was",
keywords = "Brain tumor, DCE MRI, DSC MRI, Ferumoxytol, Pediatric",
author = "Thompson, {Eric M.} and Guillaume, {Daniel J.} and Edit D{\'o}sa and Xin Li and Kellie Nazemi and Seymur Gahramanov and Bronwyn Hamilton and Edward Neuwelt",
year = "2012",
month = "8",
doi = "10.1007/s11060-012-0872-x",
language = "English (US)",
volume = "109",
pages = "105--114",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors

AU - Thompson, Eric M.

AU - Guillaume, Daniel J.

AU - Dósa, Edit

AU - Li, Xin

AU - Nazemi, Kellie

AU - Gahramanov, Seymur

AU - Hamilton, Bronwyn

AU - Neuwelt, Edward

PY - 2012/8

Y1 - 2012/8

N2 - Ferumoxytol, an iron nanoparticle used as an intravascular contrast agent for perfusion magnetic resonance imaging (MRI), has never been explored in the pediatric population. The purpose of this prospective study is to characterize the vascular and permeability properties of pediatric brain tumors using two contrast agents during a single imaging session: ferumoxytol for dynamic susceptibility weighted contrast (DSC) MRI and gadoteridol for dynamic contrast-enhanced (DCE) MRI. In a single imaging session, patients received intravenous ferumoxytol for DSC MRI followed by gadoteridol for DCE MRI. Relative cerebral blood volume (rCBV), relative cerebral blood flow (rCBF), transfer coefficient (Ktrans), and extravascular extracellular space volume fraction (ve) of the brain lesions were calculated. Patients underwent serial imaging sessions over the course of 2 years. Of the 7 patients enrolled thus far, none has experienced an adverse event. Two patients with medulloblastoma were enrolled preoperatively. In the first, rCBVmax, rCBF, Ktrans max, and ve max values were 3.74, 3.12, 0.47 min -1, and 0.08, respectively, while in the second patient, rCBVmax, rCBF, Ktrans max, and ve max values were 4.72, 3.47, 0.60 min-1, and 0.05, respectively. Four patients were enrolled after new gadolinium enhancement was noted in the tumor resection cavity. In 80 % of these lesions, rCBV was

AB - Ferumoxytol, an iron nanoparticle used as an intravascular contrast agent for perfusion magnetic resonance imaging (MRI), has never been explored in the pediatric population. The purpose of this prospective study is to characterize the vascular and permeability properties of pediatric brain tumors using two contrast agents during a single imaging session: ferumoxytol for dynamic susceptibility weighted contrast (DSC) MRI and gadoteridol for dynamic contrast-enhanced (DCE) MRI. In a single imaging session, patients received intravenous ferumoxytol for DSC MRI followed by gadoteridol for DCE MRI. Relative cerebral blood volume (rCBV), relative cerebral blood flow (rCBF), transfer coefficient (Ktrans), and extravascular extracellular space volume fraction (ve) of the brain lesions were calculated. Patients underwent serial imaging sessions over the course of 2 years. Of the 7 patients enrolled thus far, none has experienced an adverse event. Two patients with medulloblastoma were enrolled preoperatively. In the first, rCBVmax, rCBF, Ktrans max, and ve max values were 3.74, 3.12, 0.47 min -1, and 0.08, respectively, while in the second patient, rCBVmax, rCBF, Ktrans max, and ve max values were 4.72, 3.47, 0.60 min-1, and 0.05, respectively. Four patients were enrolled after new gadolinium enhancement was noted in the tumor resection cavity. In 80 % of these lesions, rCBV was

KW - Brain tumor

KW - DCE MRI

KW - DSC MRI

KW - Ferumoxytol

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=84864282730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864282730&partnerID=8YFLogxK

U2 - 10.1007/s11060-012-0872-x

DO - 10.1007/s11060-012-0872-x

M3 - Article

C2 - 22528798

AN - SCOPUS:84864282730

VL - 109

SP - 105

EP - 114

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -